Welcome to our dedicated page for Corcept Therapeutics SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Corcept Therapeutics Inc. (CORT) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI-powered summaries that help explain their contents. Corcept is a Nasdaq-listed, commercial-stage pharmaceutical company focused on cortisol modulation in endocrinologic, oncologic, metabolic and neurologic disorders, and its filings offer detailed insight into this business.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Corcept describes its commercial activities with Korlym, which it identifies as the first FDA-approved medication for patients with endogenous hypercortisolism, as well as its research and development programs in hypercortisolism, solid tumors, ALS and liver disease. These periodic reports typically discuss product revenue, research and development spending, and risks related to drug development and regulation.
Current reports on Form 8-K, some of which are summarized in the data provided, disclose material events such as quarterly financial results, submission and FDA acceptance of New Drug Applications for relacorilant in hypercortisolism and platinum-resistant ovarian cancer, a Marketing Authorization Application to the European Medicines Agency, and the receipt of an FDA Complete Response Letter for relacorilant in hypertension secondary to hypercortisolism. Other 8-K filings describe corporate developments, including changes to distribution agreements for Korlym and board-level changes accompanied by consulting arrangements.
On this page, users can review Corcept’s Forms 10-K, 10-Q and 8-K as they are made available from EDGAR, while AI-generated highlights point out key topics such as clinical trial updates, regulatory milestones, revenue trends and significant contracts. The filings section also surfaces exhibits referenced in 8-Ks, helping investors and researchers understand how Corcept’s cortisol-modulation strategy, pipeline progress and commercial operations are reflected in its official regulatory reporting.
Corcept Therapeutics officer Sean Maduck, President of Corcept Endocrinology, reported several indirect ownership changes in Corcept common stock dated January 8, 2026. Entities associated with him made bona fide gifts of 20,570 and 34,000 shares held indirectly through the Sean and Molly Maduck Living Trust and a related trust, each at a stated price of $0.00 per share. Corresponding entries show 20,570 shares held by MMM 2025, LLC and 34,000 shares held by the SNM 2026 Grantor Retained Annuity Trust, both entities associated with Maduck. He also reports 8,179 shares held directly, which include unvested restricted stock awards scheduled to vest one year after their respective grant dates if service conditions are met, plus additional indirect holdings through another grantor retained annuity trust and Duckhill Capital, LLC.
Corcept Therapeutics Incorporated received an updated ownership report from investment manager Renaissance Technologies LLC and its parent, Renaissance Technologies Holdings Corporation. As of December 31, 2025, they report beneficial ownership of 5,758,528 shares of Corcept common stock, representing 5.47% of the outstanding class.
Renaissance reports sole power to vote and dispose of all these shares, with no shared voting or dispositive power. The filing notes that certain funds managed by Renaissance Technologies LLC have the right to receive dividends and sale proceeds, and states the position is held in the ordinary course of business, not to change or influence control of Corcept.
Corcept Therapeutics Chief Scientific Officer Hazel Hunt reported an option exercise and related share withholding. On February 9, 2026, Hunt exercised stock options for 150,000 shares of common stock at an exercise price of $3.88 per share, converting a stock option that was fully exercisable and scheduled to expire on February 26, 2026.
To cover the option exercise price and associated tax withholding in a net (cashless) transaction, 77,968 common shares were withheld at a price of $41.31 per share. After these transactions, Hunt directly held 255,437 shares of Corcept Therapeutics common stock.
Corcept Therapeutics Chief Development Officer William Guyer reported an option exercise and share sale. On February 3, 2026, he exercised a stock option for 20,000 shares of common stock at $21.65 per share and then sold 20,000 shares at a weighted average price of $40.8667 under a prearranged Rule 10b5-1 trading plan adopted on November 27, 2024. After these transactions, he directly held 1,235 shares of common stock and 230,000 stock options that are fully exercisable.
Corcept Therapeutics insider William Guyer has filed to sell 20,000 shares of common stock under Rule 144. The planned sale, through broker Stifel Nicolaus & Company on NASDAQ, has an aggregate market value of
The shares to be sold were acquired on
Corcept Therapeutics director Leonard G. Baker Jr. reported multiple stock option exercises on January 27, 2026, converting options into blocks of 25,000–30,000 common shares at exercise prices between $5.86 and $15.15. These transactions are coded as option exercises, not open-market sales.
After the reported transactions, a trust for which he serves as trustee holds 1,095,262 Corcept common shares indirectly, and a limited partnership associated with a trust of which he is trustee holds 3,308,303 shares. He also directly holds 1,046,631 shares. The filing states he disclaims beneficial ownership in the trust and partnership shares except for his pecuniary interest.
Corcept Therapeutics announced that ROSELLA, its pivotal Phase 3 clinical trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer, met its overall survival primary endpoint. This means the treatment combination achieved its main goal of improving how long patients live in this hard-to-treat setting. The company shared this outcome through a press release attached as an exhibit, signaling a key late-stage milestone for relacorilant in oncology.
Corcept Therapeutics Chief Development Officer William Guyer reported option exercises and share sales in company stock. On January 6, 2026, he exercised a stock option for 20,000 shares of common stock at an exercise price of $21.65 per share and then sold 20,000 shares of common stock at a weighted average price of $35.1828 per share. The filing notes that the sale prices ranged from $34.96 to $35.50 per share. These transactions were made under a Rule 10b5-1 trading plan adopted on November 27, 2024. After the transactions, Guyer directly held 1,235 shares of common stock and 250,000 stock options that are reported as fully exercisable.
Corcept Therapeutics Inc. insider plans another share sale. A Form 144 notice discloses an intended sale of up to 20,000 shares of Corcept common stock through Stifel Nicolaus & Company Inc. on or about 01/06/2026, with an indicated aggregate market value of $699,000.00. The filing notes that 105,190,000 Corcept common shares were outstanding, providing context for the size of the planned transaction.
The 20,000 shares to be sold were acquired on 01/06/2026 via a stock option exercise from Corcept Therapeutics Inc., paid in cash. Over the prior three months, the same seller, William Guyer, reported three separate sales of 20,000 Corcept common shares each (on 10/07/2025, 11/05/2025, and 12/02/2025) with gross proceeds of $1,798,781.00, $1,507,121.00, and $1,601,525.00, respectively.
Corcept Therapeutics director James N. Wilson reported several internal movements of Corcept common stock among family-related entities on December 12, 2025. A family trust disposed of 400,000 shares as a gift at a reported price of $0.00 per share, leaving 1,045,168 shares held indirectly through the James N. Wilson and Pamela D. Wilson Trust.
Two 2025 grantor retained annuity trusts each received 200,000 shares without consideration and are reported as indirectly holding 200,000 shares apiece. The report also lists 901,067 shares of Corcept common stock held indirectly through James and Pamela Wilson Family Partners, over which Wilson has voting power pursuant to voting agreements while disclaiming beneficial ownership except to the extent of his pecuniary interest.
FAQ
What is the current stock price of Corcept Therapeutics (CORT)?
What is the market cap of Corcept Therapeutics (CORT)?
